A randomized phase II study of irinotecan plus cisplatin versus irinotecan plus capecitabine with or without isosorbide-5-mononitrate in advanced non-small-cell lung cancer

Annals of Oncology

Volumn 23, Issue 11, 2012, Pages 2925-2930

  Han, J Y ^a   Nam, B H ^a   Kim, H Y ^a   Yoon, S J ^a   Kim, H T ^a   Lee, J S ^a  

^a National Cancer Center   (South Korea)

Author keywords

ISMN; NO; NSCLC

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; IRINOTECAN; ISOSORBIDE 5 NITRATE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PIGMENTATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; ISOSORBIDE DINITRATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NITROGLYCERIN; TREATMENT OUTCOME;

EID: 84868135039     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds122     Document Type: Article

References (29)

1. D'Addario G, Pintilie M, Leighl NB et al. Platinum-based versus non-platinumbased chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 2005; 23: 2926-2936.
2. Kubota K, Kawahara M, Ogawara M et al. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-smallcell lung cancer: a randomised, open-label, phase III study. Lancet Oncol 2008; 9: 1135-1142.
3. Han JY, Lee DH, Song JE et al. Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first-line chemotherapy withsecond-line crossover in patients with advanced nonsmall cell lung cancer. Cancer 2008; 113: 388-395.
4. Han JY, Lee DH, Kim HY et al. A Phase II study of weekly irinotecan and capecitabine in patients with previously treated non-small cell lung cancer. Clin Cancer Res 2003; 9: 5909-5914.
5. Han JY, Lee DH, Lee SY et al. Phase II study of weekly irinotecan plus capecitabine for chemotherapy-naive patients with advanced nonsmall cell lung carcinoma. Cancer 2005; 104: 2759-2765.
6. Han JY, Lee DH, Kim HY et al. A phase II study of weekly docetaxel plus capecitabine for patients with advanced nonsmall cell lung carcinoma. Cancer 2003; 98: 1918-1924.
7. Lee JJ, Han JY, Lee DH et al. A phase II trial of docetaxel plus capecitabine in patients with previously treated non-small cell lung cancer. Jpn J Clin Oncol 2006; 36: 761-767.
8. Yasuda H, Yamaya M, Nakayama K et al. Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 2006; 24: 688-694.
9. Yasuda H. Solid tumor physiology and hypoxia-induced chemo/radio-resistance: novel strategy for cancer therapy: nitric oxide donor as a therapeutic enhancer. Nitric Oxide 2008; 19: 205-216.
10. Matthews NE, Adams MA, Maxwell LR et al. Nitric oxide-mediated regulation of chemosensitivity in cancer cells. J Natl Cancer Inst 2001; 93: 1879-1885.
11. Frederiksen LJ, Sullivan R, Maxwell LR et al. Chemosensitization of cancer in vitro and in vivo by nitric oxide signaling. Clin Cancer Res 2007; 13: 2199-2206.
12. Pipili-Synetos E, Papageorgiou A, Sakkoula E et al. Inhibition of angiogenesis, tumour growth and metastasis by the NO-releasing vasodilators, isosorbide mononitrate and dinitrate. Br J Pharmacol 1995; 116: 1829-1834.
13. Soon YY, Stockler MR, Askie LM et al. Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin Oncol 2009; 27: 3277-3283.
14. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
15. Simon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials. Cancer Treat Rep 1985; 69: 1375-1381.
16. Han JY, Park K, Kim SW et al. First-SIGNAL: First line Single agent Iressa versus Gemcitabine and cisplatin trial in Never-smokers with Adenocarcinoma of the Lung. J Clin Oncol 2012; 30: 1122-1128.
17. Fossella FV, DeVore R, Kerr RN et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000; 18: 2354-2362.
18. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-1597.
19. Shepherd FA, Rodrigues PJ, Ciuleanu T et al. Erlotinib in previously treated nonsmall-cell lung cancer. N Engl J Med 2005; 353: 123-132.
20. Kim ES, Hirsh V, Mok T et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008; 372: 1809-1818.
21. Rabinowitz B, Hod H, Chouraqui P et al. Hemodynamic effects of oral isosorbide-5-mononitrate and dinitrate in ischemic heart failure. Clin Cardiol 1987; 10: 603-608.
22. Gallo O, Masini E, Morbidelli L et al. Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J Natl Cancer Inst 1998; 90: 587-596.
23. Mocellin S, Bronte V, Nitti D. Nitric oxide, a double edged sword in cancer biology: searching for therapeutic opportunities. Med Res Rev 2007; 27: 317-352.
24. Wang B, Wei D, Crum VE et al. A novel model system for studying the doubleedged roles of nitric oxide production in pancreatic cancer growth and metastasis. Oncogene 2003; 22: 1771-1782.
25. Puhakka A, Kinnula V, Näpänkangas U et al. High expression of nitric oxide synthases is a favorable prognostic sign in non-small cell lung carcinoma. APMIS 2003; 111: 1137-1146.
26. Ambs S, Merriam WG, Ogunfusika MO et al. p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells. Nat Med 1998; 4: 1371-1376.
27. Vähäkangas KH, Bennett WP, Castrén K et al. p53 and K-ras mutations in lung cancers from former and never-smoking women. Cancer Res 2001; 61: 4350-4356.
28. Skaug V, Ryberg D, Kure EH et al. p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients. Clin Cancer Res 2000; 6: 1031-1037.
29. Zhou H, Huang L, Sun Y, Rigas B. Nitric oxide-donating aspirin inhibits the growth of pancreatic cancer cells through redox-dependent signaling. Cancer Lett 2009; 273: 292-299.